Biocon Biologics and Civica launch private-label Insulin glargine

Lannett receives USFDA safety review for biosimilar insulin glargine

Go-ahead for pivotal clinical trial which is expected to commence by March

Prime Therapeutics to list Semglee and Insulin Glargine

Biocon Biologics and Viatris co-developed the products

Biocon Biologics’ interchangeable biosimilar insulin Glargine preferred on Express Scripts

Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Biocon Biologics expands insulin access in Malaysia

Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served

Biocon to obtain approval for diabetes drug, Liraglutide in UK

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Biocon Biologics completes Integration of Viatris' Biosimilar business

The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone